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Background: Some of ginsenosides, root extracts from Panax ginseng, exert cytotoxicity against cancer cells
through disruption of membrane subdomains called lipid rafts. Protopanaxadiol (PPD) exhibits the highest cytotoxic
effect among 8 ginsenosides which we evaluated for anti-cancer activity. We investigated if PPD disrupts lipid rafts
in its cytotoxic effects and also the possible mechanisms.
Methods: Eight ginsenosides were evaluated using different cancer cells and cell viability assays. The potent
ginsenoside, PPD was investigated for its roles in lipid raft disruption and downstream pathways to apoptosis of
cancer cells. Anti-cancer effects of PPD was also investigated in vivo using mouse xenograft model.
Results: PPD consistently exerts its potent cytotoxicity in 2 cell survival assays using 5 different cancer cell lines.
PPD disrupts lipid rafts in different ways from methyl-β-cyclodextrin (MβCD) depleting cholesterol out of the
subdomains, since lipid raft proteins were differentially modulated by the saponin. During disruption of lipid rafts,
PPD activated neutral sphingomyelinase 2 (nSMase 2) hydrolyzing membrane sphingomyelins into pro-apoptotic
intracellular ceramides. Furthermore, PPD demonstrated its anti-cancer activities against K562 tumor cells in mouse
xenograft model, confirming its potential as an adjunct or chemotherapeutic agent by itself in vivo.
Conclusions: This study demonstrates that neutral sphingomyelinase 2 is responsible for the cytotoxicity of PPD
through production of apoptotic ceramides from membrane sphingomyelins. Thus neutral sphingomyelinase 2 and
its relevant mechanisms may potentially be employed in cancer chemotherapies.
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Ginsenosides, root extracts from ginseng have been used
in many countries for treatment and prevention of a
variety of cancers of stomach, lung, liver, pancreas,
colon and so on, since they are responsible for most of
ginseng’s pharmacological and biological effects [1].
Ginsenosides suppress proliferation and angiogenesis
of cancer cells, reduce malignant transformation, and
increase cell deaths due to apoptosis and necrosis [2,3].
They can also be used in combinations with conventional
chemotherapeutic agents for treatment of cancers and
prevention of their developments in advance.* Correspondence: hwanmook@gachon.ac.kr
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reproduction in any medium, provided the orRecent investigations have suggested that specialized
subdomains of cell membrane termed lipid rafts are ac-
tively involved in regulation of essential cellular pro-
cesses such as cell proliferation, differentiation and
apoptosis, many of which are altered during develop-
ment of various tumors [4,5]. Lipid rafts are enriched
in cholesterol, sphingomyelin, gangliosides, caveolins,
flotillins, etc. Depending on their lipid and protein
compositions, lipid rafts are classified into caveolae and
non-caveolar ones [4]. Caveolar lipid rafts are flask-shaped
membrane invaginations enriched in cholesterol and
caveolins, proteins from caveolin family, while non-caveo-
lar ones are associated with proteins of reggie family,
flotillin-1 and flotillin-2 [4]. Due to its high concentrations
in lipid rafts, long and saturated sphingolipids make mic-
rodomains physicochemically distinct from the remaining. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phospholipids through their closer interactions with cho-
lesterols [4]. Cholesterol depleting agents such as methyl-
β-cyclodextrin (MβCD) can remove cholesterols out of
lipid rafts, changing their physical properties and thereby
modifying lipid raft-dependent signaling pathways in
vital cellular processes [6]. Ginsenosides, phytosterols
from Panax ginseng, are natural cholesterol derivatives
with hydroxyl groups and oligosaccharide moieties, so
many investigators have studied effects on which these
ginsenosides might have against crucial functions of
lipid rafts.
The ginsenoside Rh2 has been known to increase
membrane fluidity and induce apoptosis via lipid raft
disruption and thereby caspase-8 dependent Fas activation
[7]. Rh2 also reduces the levels of lipid rafts in plasma
membranes by increasing their internalization through
unknown mechanisms, leading to Akt inactivation and
ensuing apoptosis [8]. 25-hydroxyprotopanaxadiol (25-
OH-PPD), another ginsenoside from Panax ginseng dem-
onstrated a potent cytotoxicity against a variety of prostate
cancer cells, compared to its related ginsenosides [9].
Anti-cancer effects against both prostate and lung cancer
cells were repeated with 25-OCH3-protopanaxadiol (25-
OCH3-PPD) from Panax notoginseng in vitro and in vivo
[10,11]. These ginsenosides modulated protein regulators
in cell proliferation and apoptosis with relatively low
toxicity against non-cancer cells. Like Rh2 inhibiting
Akt signaling in lipid rafts in favor of apoptosis, 20S-
protopanaxadiol (aPPD), another PPD derivative signifi-
cantly inhibited Akt activities only in lipid rafts with no
changes in total Akt levels of plasma membranes [12].
In present study, we have tested 8 ginsenosides from
Panax ginseng for their cytotoxicity using different cancer
cell lines. We have demonstrated that cytotoxic effects of
PPD on cancer cells were mediated through production of
intracellular ceramides from membrane sphingomyelins.
Sphingolipids such as sphingomyelins have biologically
active roles in cellular functions such as growth and differ-
entiation through production of ceramides, signaling mol-
ecules rather than structural elements in cell membrane.
In light of the fact that accumulation of intracellular ce-
ramides appeared to be important in chemosensitization
of cancer cells during chemotherapies using multiple drugs
[13], potential of the natural product as chemotherapeutic
agent are further discussed in terms of chemosensitization
of cancer cells to apoptosis. Finally, PPD demonstrated its
in vivo anti-tumor activity in mouse xenograft tumor
model, confirming its in vitro effects on cancer cells.
Methods
Cell lines and reagents
Cancer cells were obtained from American Type Culture
Collection (Rockville, MD, USA) and cultured in DMEMor RPMI-1640 medium (Gibco BRL, Grand Island, NY,
USA) supplemented with 10% fetal bovine serum (Hyclone,
Logan, UT, USA), 2 mM L-glutamine and 1% penicillin/
streptomycin (Gibco BRL) at 37°C with 5% CO2. Ginse-
nosides, including PPD (purity > 98%) were obtained from
BTGin (Daejeon, Korea). Propidium Iodide (PI) solution
was obtained from Sigma-Aldrich (St. Louis, MO, USA).
Cell viability assay
In XTT assay using Cell Proliferation Kit II (XTT) (Roche
Applied Science, Mannheim, Germany), cells were plated
into 96 well plates at 0.3 – 1.0 ×104 cells per well over-
night and treated with PPD or/and other compounds for
24 or 48 hr. After addition of XTT labeling mixture for
2 hr at 37°C, absorbance was measured at 490 nm with a
reference wavelength at 650 nm. In Sulforhodamine B
(SRB) assay described previously [14], after treatment with
various ginsenosides for 24 or 48 hr, cells were added with
50 μl 50% trichloroacetic acid (TCA), fixed for 2 h at 4°C,
washed with tap water 3 times and air-dried. TCA-fixed
cells were stained for 30 min with SRB (0.4% in 1% acetic
acid), followed by washing with 1% acetic acid and air-
dried. After addition of 100 μl 10 mM Tris, pH 10.5, ab-
sorbance was measured at 570 nm. In WST-1 assay with
EZ-Cytox Cell Viability Assay kit (Daeillab Service, Seoul,
Korea), after incubation with various ginsenosides for 24
or 48 hr, cells were added with 10 μl WST-1 reagent, then
incubated for 15 – 60 min at 37°C. Absorbance was deter-
mined at 460 nm with microtiter plate reader.
Cell cycle analysis
K562 cells were plated into 6 well plates at 3 × 105 cells
per well overnight, then treated with PPD at specified
concentrations for 48 h. In chemosensitization experi-
ments, cells were treated with PPD or Cisplatin with or
without doxorubicin for 48 hr at indicated concentrations.
After treatments, cells were harvested, washed with PBS,
fixed in 70% ethanol overnight at −20°C, stained with
propidium iodide overnight at 4°C, then analyzed using
FACSCalibur flow cytometer (BD Biosciences, San Jose,
CA, USA).
Western blotting
Whole cell proteins were separated in 8-15% SDS poly-
acrylamide gel, transferred to PVDF membranes (Pall Cor-
poration, Pensacola, FL, USA) and probed with anti-Cdk2,
anti-Cdk4, anti-caspase-9, anti-β-actin and anti-IGF-1R
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), and anti-Cdk6, anti-Cyclin A, anti-Cyclin B1, anti-
α-tubulin, anti-poly (ADP-ribose) polymerase (PARP),
anti-Bcl-2, anti-pAkt (Ser473), anti-caspase-8 and anti-Bid
(Cell Signalling Technology, Beverly, MA, USA) overnight
at 4°C. Next day, membranes were incubated with horse-
radish peroxidase (HRP)-conjugated goat anti-mouse IgG,
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Cruz) and detected with enhanced chemiluminescent
(ECL) detection system (Amerisham Biosciences, Little
Chalfont, United Kingdom).
Cell imaging
After treatment with PPD overnight as described above,
K562 cells were centrifuged and treated with 2 μM
BODIPY-C12-SM and 2 μM BODIPY-Cholesterol ester
(Invitrogen, Grand Island, NY, USA) respectively in
RPMI medium for 30 min at 4°C to label sphingomyelin
and cholesterol. After staining, cells were washed with
PBS twice and placed onto confocal stage to collect
images.
Mass spectrometry
K562 cells were seeded into petri dishes at 1 × 106 cells
per dish overnight, then treated with PPD at specified
concentrations for 6 or 16 hr. After treatments, cells
were harvested, washed twice with ice-cold PBS and
extracted with extraction buffer (isopropanol: water:
ethyl acetate = 30:10:60), as described previously [15].
Amounts of ceramides were determined with LC/MS/MS
system (LC, Thermo surveyor LC pump plus, American
Laboratory Trading, East Lyme, CT, USA; MS, LCQ Fleet,
Thermo Fisher Scientific, Waltham, MA, USA) using C-
17 ceramide as an internal standard.
Inhibition and siRNA interference
In inhibition studies, cells were plated into 96 well plates
at 0.3 – 1.0 ×104 cells per well overnight, preincubated for
1 hr with neutral sphingomyelinase 2 (nSMase 2) inhibitor
GW4869 at 10 μΜ (Sigma-Aldrich), then treated with
PPD at specified concentrations for 48 h. Two nSMase 2
siRNAs were purchased from Bioneer (Daejeon, Korea):
siRNA 1141725 sense: GCU ACU UCG AGU ACA UCC
U and antisense AGG AUG UAC UCG AAG UAG C and
siRNA 1141726 sense: CAC GAA CGG CCU GUA CGA
U and antisense: AUG GUA CAG GCC GUU CGU G.
Scrambled siRNA (SCR) (Bioneer) was used as negative
control: sense CCU ACG CCA CCA AUU UCG U and
antisense: ACG AAA UUG GUG GCG UAG G. Real-time
PCR was performed to quantify mRNA expressions of
nSMase 2 after knockdown with siRNA 1141725 and
1141726 (Additional file 1). Total RNA was isolated from
cultured cells using Trizol (Invitrogen). cDNAs were syn-
thesized using oligo (dT) and SuperScript III reverse
transcriptase (Promega, Madison, WI, USA), then ampli-
fied using iQ SYBR Green PCR Master Mix (Bio-Rad
Laboratories, Hercules, CA, USA) in conjunction with
Mx3005P QPCR Systems (Agilent Technologies, Santa
Clara, CA, USA). Primer sets were as follows: nSMase 2
qPCR primer P109289 (Bioneer); glyceraldehyde-3-phos-
phate dehydrogenase, 5′-TGGTATCGTGGAAGGACTCATGAC-3′ (forward) and 5′-ATGCCAGTGAGCTTCC
CGTTCAGC -3′ (reverse). Fold changes were calculated
after normalization to endogenous GAPDH, using com-
parative 2-ΔΔCt method [16]. In transfections, cells were
cultured in complete medium, seeded into 96 well plate
at 0.5 – 1.0 × 104 cells per well using culture media with-
out antibiotics overnight along with mixture of Lipo-
fectamine (Invitrogen) and SCR or siRNAs (Bioneer) at
10 nM. Next day, transfected cells were treated with vari-
ous concentrations of PPD for 48 hr, then were assayed
for their viabilities using WST-1, as described above.
Mouse xenograft tumor model
All animal care and experimental procedures were ap-
proved by Institutional Animal Care and Use Committee
(IACUC) at Gachon University in Incheon, Korea. In
mouse xenograft tumor model, female BALB/c nude mice
(Charles River, Wilmington, MA, USA) were subcutane-
ously injected with K562 cells to establish xenografted
tumors and provided with food and water ad libitum
under standard light/dark cycles. When K562 tumor sizes
reached 47.6 mm3, xenografted mice were randomly
assigned into 2 groups (n = 4 mice per group) to receive
daily intravenous injections with vehicle, Cisplatin (5 mg
kg-1) or PPD (25 or 50 mg kg-1 body weight) 5 days per
week over 2 weeks. Tumor volumes were measured with
calipers over 10 days as well as body weights and were
calculated using formula (width2 × length) 2-1, where width
is the smaller tumor diameter. Mice were killed on the 11th
day and their tumor weights were measured.
Statistical analysis
The values in figures were expressed as means ± s.d. Un-
paired t tests were used to compare two groups. Values
of P < 0.05, P < 0.01 and P < 0.001 were considered as
statistically significant.
Results
Protopanaxadiol exhibits the most potent cytotoxic
effects against a variety of cancer cells among 8
ginsenosides tested in cell survival assays
Eight ginsenosides extracted from Panax ginseng were
evaluated for their in vitro cytotoxic activities against 5
human cancer cell lines (Figure 1, Additional files 2 and
3), using 2 different cell viability assays. Most of cell via-
bility assays measure specific components of live cells, so
results could be varied depending on each assay method.
Here, we employed XTT and SRB assays to more convin-
cingly examine effects of 8 ginsenosides on various cancer
cells. SRB assay measures total biomass, namely number
of cells, by staining cellular proteins with Sulforhodamine
B, whereas dye reduction by mitochondrial reductants on
cell surface is determined in XTT assay, actually measur-
ing pyridine nucleotide redox status of live cells [14,17].
Figure 1 Protopanaxadiol (PPD) exhibited the most potent cytotoxic effects on cancer cells of various malignancies. K562 cells were
treated with PPD at 0, 25 or 50 μM for 24 or 48 hr, then their viabilities were assessed using XTT (A) and SRB assays (B). *, p < 0.05; **, p < 0.01;
***, p < 0.001 for control (vehicle) are considered as significant.
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cells, PC-3 prostate cancer cells, ACHN and Caki-1 renal
cancer cells, and K562 leukemia cells, since ginsenosides
might have cell type- or tissue-specific cytotoxic effects.
PPD significantly reduced viabilities of 5 different cancer
cells at various concentrations for 24 or 48 hours as well
as compound K both in dose- and time-dependent ways
(Figure 1, Additional files 2 and 3). PPD is a tetracyclic tri-
terpene saponin which has a 4 ring backbone structure
and 3 hydroxyl groups attached with structural resem-
blance to cholesterol (Figure 2A) [1]. Cell survival assays
using additional cancer cell lines of different malignancies
were employed to quantitatively measure GI50′s of PPD
against a variety of cancer cells, which are the concentra-
tions of PPD to inhibit cell survival by 50% (Figure 2B).
Most of cancer cell lines tested exhibited their GI50 values
between 20 μM and 50 μM with a couple of exceptions.
Colon cancer cells (HT29, HCT116 and HCT15) and
gastric cancer cells (MKN28) appeared to be more re-
sistant to PPD than other cancer cells such as K562
(leukemia), NCI-H23 and A549 (lung), Caki-1 (renal),Figure 2 A variety of cancer cells showed high to moderate sensitivit
calculated against 13 cancer cell lines. GI50 is the concentration that inhibitPC-3 and DU145 (prostate), MDA-MB-231 (breast),
NUGC-3(gastric), SK-OV-3 (ovarian), indicating that anti-
cancer activities of PPD might be cell type- or tissue-
specific (Figure 2B).
PPD inhibits cell proliferation through modulation of cell
cycle regulators as well as apoptotic proteins, leading to
cell death
In cell cycle analysis using flow cytometry, PPD arrested
cell cycle in SubG1 phase, which contains mostly dead
cells (Figure 3A and C). Significant numbers of cells from
G1, S and G2/M phases turned into fragmented dead cells
of subG1 phase in dose-dependent way, as PPD concen-
tration increased up to 50 μM. Thus, cell cycle regulators
such as cyclins and cyclin dependent kinases (cdks) are
likely to be modulated by PPD as well as proteins in cell
death pathways. Cdk2 regulates cell cycle during G1 to S
and S to G2/M phase transitions through its interaction
with cyclin A or E, while cdk4 and cdk6 are essential for
cell cycle progression during G1 phase and G2 to M tran-
sition respectively in concert with cyclin D. In agreementies to PPD treatment. (A) Structure of PPD. (B) GI50’s of PPD was
s cell growth by 50%.
Figure 3 Effects of PPD on cell cycle progression of cancer cells were analyzed using flow cytometry. (A) K562 cells were exposed to PPD
at 0, 12.5, 25 and 50 μM for 48 hr. Then, they were fixed with ethanol, stained with propidium iodide and analyzed using flow cytometry. (B)
K562 cells were exposed to PPD at 0, 12.5 and 25 μM for 24 hr, then expression levels of cell cycle regulators and pro-apoptotic proteins were
determined with Western blotting using anti-cdk2, -cdk4, -cdk6, -cyclinA and -cyclinB1 antibodies, -PARP, -Bcl-2, and -caspase-9 antibodies. (C)
Relative percentages of cells were calculated at sub-G1, G1, S and G2/M phases. (D) All experiments were repeated three times with similar results,
so the means ± standard deviations of band intensities were calculated in our Western blot analyses for cell cycle and apoptosis components.
*, p < 0.05; **, p < 0.01; ***, p < 0.001 for control (vehicle) are considered as significant.
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cyclins were downregulated in Western blot analysis of
PPD treated K562 cells (Figure 3B and D). In addition,
cleaved active form of caspase-9 was increased as well
as cleaved caspase-3 substrate PARP, while anti-apop-
totic protein Bcl-2 was downregulated, indicating that
apoptotic proteins are also modulated by PPD (Figure 3B
and D).
The ginsenoside mediates anti-cancer activities by
disrupting lipid rafts in plasma membrane
We investigated the possibility that PPD may disrupt
lipid rafts as one of cytotoxic mechanisms like Rh2 and
aPPD [7,8,12]. K562 and HT29 cells were treated with
PPD with or without MβCD, another lipid raft disrupter
[6]. MβCD minimally enhanced cytotoxic effects of PPD
against both cancer cells, indicating that PPD might act
through common mechanisms with those of MβCD des-
pite possible distinct pathways (Figure 4A). As shown in
Figure 4B and C, PPD and MβCD modulate lipid raft-
dependent signaling pathways including IGF-1R, pAkt,PARP, Caspase-8 and Bid in two different cancer cells.
Interestingly, two lipid raft disrupters differentially mod-
ulated IGF-1R and Bid, although they exhibited similar
expression patterns in the remaining lipid raft proteins
under investigation. Both MβCD and PPD decreased le-
vels of IGF-1R as well as Bid in K562 cells, while IGF-1R
and Bid were upregulated by PPD and MβCD respectively
in HT29 cells, suggesting that cytotoxicity of PPD and
MβCD is cell type-specific (Figure 4B and D).
PPD exerts its cytotoxic effects on cancer cells through
upregulation of neutral sphingomyelinase 2
We hypothesized that PPD might have common mech-
anism(s) among cell type-specific cytotoxic effects in dis-
tinct cancer cells. To this end, we visualized cholesterols
and sphingomyelins rich in the microdomains with fluor-
escent sphingomyelin and cholesterol (Figure 5A). PPD
treatment removed sphingomyelins out of cell mem-
branes without any significant reduction of membrane
cholesterols (Figure 5A), suggesting that the ginsenoside
might modulate signaling pathways through lipid rafts
Figure 4 PPD disrupted lipid rafts in plasma membranes of cancer cells through cell type specific mechanisms. (A) K562 and HT29 cells
were exposed to PPD at 0, 25 and 50 μM in presence of 0, 0.5, 1.0 or 2.5 mg/ml MβCD for 24 hr. The cell viabilities were measured using WST-1
assay. (B) K562 and HT29 cells were exposed to MβCD at 0, 1.0 or 2.5 mg/ml and PPD at 0, 25 or 50 μM for 24 hr, then expression levels of lipid
raft-associated proteins were determined with Western blotting using anti-IGF-1R, -pAkt, -caspase-8, -PARP, and -Bid antibodies. (C) All
experiments were repeated three times with similar results, so the means ± standard deviations of band intensities were calculated in our
Western blot analyses for lipid raft-associated proteins. *, p < 0.05; **, p < 0.01; ***, p < 0.001 for control (vehicle) are considered as significant.
Figure 5 PPD exerted its cytotoxic effects on cancer cells through activation of neutral sphingomyelinase 2. (A) K562 cells were exposed
to PPD at 0 (DMSO) and 25 μM for 24 hr. They were stained with BODIPY-Cholesterol ester or BODIPY-C12-SM, then examined using confocal
microscopy. (B) K562 cells were exposed to PPD at 0, 12.5, 25 and 50 μM for 6 or 16 hr, then levels of different ceramides were analyzed using
LC-MS/MS. K562 (C) and HT29 (D) cells were preincubated with neutral sphingomyelinase (nSMase) inhibitor GW4869 for 1 hr, exposed to PPD at
0, 25 and 50 μM for 48 hr and evaluated for cell viabilities using WST-1 assay. Inhibition studies with GW4869 were repeated three times with
similar results. K562 (E) and HT29 (F) cells were transfected with nSMase 2 siRNA 1141725, exposed to PPD at 0, 6.25, 12.5, 25 and 50 μM for
48 hr and evaluated for cell viabilities using WST-1 assay. Inhibition studies with siRNA transfections were repeated twice with similar results.
*, p < 0.05; **, p < 0.01; ***, p < 0.001 for control (vehicle) are considered as significant.
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Figure 6 PPD sensitized cancer cells to doxorubicin treatment. K562 (A and B) and HT29 (C and D) cells were exposed to Cisplatin (A and
C) or PPD (B and D) at 0, 25 and 50 μM in presence of 0, 0.25, 1.0 or 2.5 μM Doxorubicin for 48 hr. All experiments were repeated three times
with similar results.
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sphingomyelins disappearing in plasma membrane, we
measured intracellular levels of various ceramides, the im-
mediate degradation products of sphingomyelins after
PPD treatments for 6 and 16 hr, using mass spectrom-
etry (Figure 5B). Levels of ceramides in cell lysates were
significantly increased in dose-dependent way as PPD
concentration reached 50 μM both at 6 and 16 hr. The
production of intracellular ceramides induces apoptosis
in different cancer cells, thus increased levels of cellular
ceramides are likely to be responsible for the reduced
survival of PPD-treated K562 and HT29 cells [18,19].
Then, we hypothesized that PPD induced cancer cell
deaths could be reversed by knockdown or inhibition of
sphingomyelinase, which degrades membrane sphingo-
myelins into ceramides. To this end, we knocked down
neutral sphingomyelinase 2 with si-RNA transfection
or inhibited its enzyme activity with an inhibitor
GW4869 (Figure 5C - F). Blockage of the responsible
neutral sphingomyelinase 2 decreased PPD-induced cell
deaths in K562 and HT29 cells to significant extent.
Therefore, these results demonstrate that PPD converts
membrane sphingomyelins into intracellular ceramides
through activation of neutral sphingomyelinase 2 as
one of its major cytotoxic mechanisms.PPD greatly sensitizes cancer cells to cell death by
anti-cancer drugs such as Doxorubicin
Previous studies have shown that endogenous and cell
permeable exogenous ceramides demonstrated pro-apop-
totic activities against a variety of cancer cells [18-20].
Thus, biologically active ceramides have gotten a great
deal of attentions in cancer chemotherapeutics in that they
could be utilized as potential targets to enhance effective-
ness of conventional anti-cancer drugs such as doxorubi-
cin in a synergistic way [21]. Here, we demonstrated that
PPD greatly sensitizes K562 and HT29 cells to doxorubi-
cin to similar extent where Cisplatin does in additive or
synergistic ways, depending on different combinations of
their concentrations (Figure 6A-D). Although there were
some differences in sensitivities of two cell types, PPD
induced chemosensitization seemed dose-dependent but
not cell type-specific. Thus our protopanaxadiol could be
an effective adjunct to chemotherapies using highly toxic
anti-cancer drugs such as Doxorubicin through their re-
duced usages, although complete molecular mechanisms
of additive or synergistic effects remain to be determined.
PPD enhanced sensitivities of cancer cells to Doxorubicin
through the increased growth inhibition and apoptosis just
like Cisplatin does, as shown in cell cycle analyses using
flow cytometry (Figure 7A-D).
Figure 7 Sensitization by PPD is mediated through altering cell cycle progression and apoptosis. K562 cells were exposed to Cisplatin
(A and B) or PPD (C and D) at 0, 25 or 50 μM with or without 0.25 μM Doxorubicin for 48 hr. Then they were fixed with ethanol, stained with
propidium iodide and analyzed using flow cytometry. All experiments were repeated three times with similar results.
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against xenografted K562 cancer cells
We next tested the potent in vitro cytotoxicity of PPD
against cancer cells in vivo using mouse xenograft tumor
model. K562-xenografted tumors on BALB/c nude mice
were treated daily with vehicle, Cisplatin (5 mg kg-1 body
weight) or PPD (25 or 50 mg kg-1 body weight), once
their sizes reached 47.6 mm3. Both PPD and Cisplatin
started reducing tumor volumes compared to control
group from the first day after drug treatments, with total
tumor volumes decreased by 51.7% with Cisplatin and
by 49.2% with PPD on the 11th day (Figure 8A). How-
ever, weight losses in PPD-treated mice were less severe
than in Cisplatin-treated ones during the early days, sug-
gesting that PPD might be rather safer as a novel che-
motherapeutic agent, although both PPD and Cisplatin
didn’t induce any significant changes in mouse body
weights later despite their potent anti-tumor activities
(Figure 8B and C).Discussion
Novel therapeutic agents, giving better efficacy but less
toxicity and resistance, have been in great need to treat a
variety of cancers refractory to our current cancer thera-
peutics, thereby resulting in poor outcomes even after
intensive treatments. More than 30 ginsenosides iden-
tified from ginseng extracts largely consist of four ring
structures of 17 carbons derived with multiple sugar
moieties [1]. Despite variable effectiveness, their poten-
tial as an adjunct to cancer therapeutics has been inves-
tigated for a long time due to their potent cytotoxicity
against cancer cells but still low toxicity on non-cancer
cells. In present investigation, the potent protopanaxadiol
illustrated multifaceted aspects of its cytotoxicity through
modulation of multiple cell cycle regulators and cell death
proteins in cell cycle analyses.
Although PPD disrupts lipid rafts through certain com-
mon mechanisms with cholesterol depletion by MβCD,
some PPD-specific modulation of essential signaling path-
Figure 8 PPD reduced both tumor volumes and weights in in vivo xenograft mouse model. K562-xenografted BALB/c nude mice were
randomly divided and treated daily with vehicle, Cisplatin (5 mg/kg) or PPD (25 or 50 mg/kg), when their tumor volumes reached 47.6 mm3.
(A) The tumor volumes were determined using the formula (width2 × length)/2, where width represents the smaller diameter. (B) The body
weights were measured daily during treatments. Body weight changes were given as percentage of mouse body weights on day 0. (C) The
tumor weights were measured on the final 11th day. Unpaired Student’s t test was used for comparisons between control (vehicle) and Cisplatin
or PPD group. *, p < 0.05; **, p < 0.01; ***, p < 0.001 for control (vehicle) and Cisplatin, and †, p < 0.05; ††, p < 0.01; †††, p < 0.001 for control
(vehicle) and PPD are considered as significant.
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demonstrated that some lipid raft-associated signaling
proteins are modulated by other ginsenosides such as Rp1,
aPPD and Rh2 [7,8,12,22]. Rp1 inhibited proliferation of
human breast cancer cells such as MCF-7 and MDA-MB-
231 through suppression of IGF-1R/pAkt pathway, pAkt
of which is also suppressed by Rh2 and aPPD [5,8,12,22].
Activation of IGF pathway is a crucial prerequisite to
malignant transformation during development of various
cancers as well as differentiation of normal cells such as
adipocytes [23,24]. IGF-1R is overexpressed in most can-
cer cells, so it’s not surprising that some tumor supp-
ressors exert anti-cancer activity through transcriptional
suppression of IGF-1R gene [25]. In Western blot analysis,
IGF-1R was downregulated by MβCD and PPD in K562
cells, whereas surprisingly, PPD upregulated IGF-1R in
HT29 cells, suggesting that IGF-1R might have a minor
role in cytotoxicity of PPD on HT29 cells due to other
potent cytotoxic mechanisms. Another ginsenoside Rg1
attenuated cytotoxic effects of neurotoxin 6-OHDA onhuman neuroblastoma cells through IGF-1R receptor sig-
naling [26], indicating that ginsenoside-mediated IGF-1R
signaling is cell-type specific depending on agents used.
Interestingly, MβCD also had a cell-type specific effect in
K562 and HT29 cells, since Bid was upregulated in HT29
cells despite its lower level in K562 cells. Since lipid rafts
are essential for cancer development, ability of PPD to dis-
rupt the microdomains can be employed as a chemothe-
rapeutic target for cancer treatments, as shown in other
ginsenosides such as aPPD and Rh2 [7,12]. In addition,
Rh2-induced Fas activation and its synergism with be-
tulinic acid toward apoptosis of cancer cells through
caspase-8 activation made this lipid raft disruptor an ad-
junct candidate for anti-cancer therapies [7,27].
Intracellular levels of ceramides are modulated through
hydrolysis of sphingomyelins by sphingomyelinases, de
novo synthesis involving ceramide synthases and produc-
tion of pro-survival molecule, sphingosine 1-phosphate
from ceramide by sphingosine kinases [28]. Both neutral
sphingomyelinases (nSMases) and acid sphingomyelinases
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myelins in response to apoptotic inducers including che-
motherapeutic agents [18,20,29]. In our efforts to identify
PPD-specific cytotoxic mechanisms in lipid rafts, we dem-
onstrated that accumulated intracellular ceramides medi-
ate cytotoxic effects of PPD, leading to growth inhibition
and apoptosis in distinct cancer cells. Since knockdown
or inhibition of neutral sphingomyelinase 2 reduced PPD
induced cytotoxic effects against cancer cells to significant
extent, this enzyme must be at least partially responsible
for growth arrest and apoptosis of cancer cells through
increasing intracellular ceramide levels. A recent publica-
tion has shown that Withanolide D, an herbal compound
from Withania Somnifea, also activated neutral sphing-
omyelinase 2/ceramide pathway, inducing apoptosis in
leukemia cells [19]. To our knowledge, we have demon-
strated for the first time that PPD, one of ginsenosides
from Panax ginseng, mediates its cytotoxicity against can-
cer cells through production of intracellular ceramides by
upregulation of neutral sphingomyelinase 2.
We also demonstrated that PPD could significantly en-
hance Doxorubicin induced cell deaths in two different
cancer cell lines as an effort to reduce the usage of toxic
anti-cancer drugs. Cisplatin activates acid sphingomy-
elinase, followed by production of ceramides, leading to
CD95 redistribution in lipid rafts and thereby apoptosis
of human colon cancer cells, so its chemosensitization
of cancer cells to Doxorubicin could also be acid sphin-
gomyelinase/ceramide-dependent [30,31]. Acid sphingo-
myelinase transfection increased intracellular levels of
ceramides in glioma cells, thereby sensitizing the cells to
chemotherapy via production of reactive oxygen species
[32]. This ceramide based synergistic mechanism was
also shown by exogenous C6 ceramide which was able
to sensitize multiple cancer lines to Doxorubicin in-
duced apoptosis [21]. Given that Doxorubicin induced
cancer cell deaths through production of endogenous
ceramides as one of its mechanisms [13], it is quite con-
ceivable that the additive effect or synergism of PPD might
come from common pathway or mechanism including ce-
ramides between two chemotherapeutic agents, although
the detailed mechanisms will have to wait for further inves-
tigations in the future. In mouse xenograft model, doses of
PPD tested showed anti-tumor activities comparable to
Cisplatin which has shown its in vivo synergistic effects
with Doxorubicin [33], although in vivo chemosensitization
of PPD to Doxorubicin remains to be determined.
Conclusions
In conclusion, we have identified the hydrolysis of mem-
brane sphingomyelins into ceramides by neutral sphin-
gomyelinase 2 as one of major mechanisms by which PPD
exerts its cytotoxic effects against a spectrum of cancer
cells, although further investigations are needed to fullyunderstand them. Thus neutral sphingomyelinase 2 and
its relevant mechanisms could potentially be employed in
cancer chemotherapies. This investigation also demon-
strated the potential of PPD as a potent adjunct to conven-
tional anti-cancer drugs in combinational chemotherapies
as well as a novel agent by itself. Thus, the clinical use of
PPD as adjunct is likely to reduce toxic side effect of anti-
cancer drugs and occurrence of drug resistances due to use
of single agents at high doses during chemotherapies.
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Additional file 1: Real-time PCR analysis. Neutral sphingomyelinase 2
expression was decreased in nSMase 2 siRNA knocked down K562 (A)
and HT29 (B) cells. The nSMase 2 mRNA levels were normalized against a
house keeping gene, GAPDH. Fold changes were calculated relative to
control. *, p < 0.05; **, p < 0.01; ***, p < 0.001 for control (vehicle) are
considered as significant.
Additional file 2: Protopanaxadiol (PPD) exhibits potent cytotoxic
effects on other cancer cells than K562 in XTT assay. ACHN (A), PC-3
(B) NCI-H23 (C) and Caki-1 (D) cells were treated with PPD at 0, 25 or
50 μM for 24 and 48 hr, then their viabilities were assessed using XTT
assay. *, p < 0.05; **, p < 0.01; ***, p < 0.001 for control (vehicle) are
considered as significant.
Additional file 3: Protopanaxadiol (PPD) exhibits potent cytotoxic
effects on other cancer cells than K562 in SRB assay. ACHN (A), PC-3
(B) NCI-H23 (C) and Caki-1 (D) cells were treated with PPD at 0, 25 or
50 μM for 24 and 48 hr, then their viabilities were assessed using SRB
assay. *, p < 0.05; **, p < 0.01; ***, p < 0.001 for control (vehicle) are
considered as significant.
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